Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00509548Phase 2Terminated

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

Role: lead

NCT00631462Phase 1Completed

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

Role: lead

NCT00103350Phase 1Completed

Safety of TG100-115 for Heart Attack Treated With Angioplasty

Role: lead

NCT00414999Phase 1Completed

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

Role: lead

All 4 trials loaded